Literature DB >> 21989992

Comparison of the BASDAI and the miniBASDAI in assessing disease activity in patients with ankylosing spondylitis.

Jinane Hakkou1, Samira Rostom, Nawal Aissaoui, Kenza Berrada Ghezioul, Rachid Bahiri, Redouane Abouqal, Najia Hajjaj-Hassouni.   

Abstract

The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) is the most widely used instrument for the assessment of disease activity in ankylosing spondylitis (AS). Objective. The aims to investigate whether the alternative BASDAI, here termed as the miniBASDAI [(Question (Q) 1 fatigue + Q2 spinal pain) + mean of (Q5 strength morning stiffness + Q6 duration morning stiffness)] / 3], measures disease activity more accurately in the subgroup of AS patients without peripheral manifestations. One hundred and ten patients were included in this cross-sectional study according to the modified New York criteria for AS. Clinical and biological parameters were evaluated. The disease activity was evaluated by the BASDAI. We calculated the miniBASDAI by omitting both the peripheral joints and the enthesitis questions: questions 3 and 4. Patients were dichotomized into a "P+" group if peripheral manifestations were present (at least arthritis or enthesitis) and a "P-" group, the subgroup without peripheral involvement (with either arthritis or enthesitis). Correlation of the BASDAI and miniBASDAI with other disease parameters were examined with the Spearman's rank correlation analysis. One hundred and ten patients were recruited. The percentage of patients with pure axial disease manifestation without peripheral involvement "P - group" was 42.7%. We found a similarly good correlation of the miniBASDAI with patient global, physician on disease activity, BASFI, ESR and CRP if compared to the correlation of the original BASDAI with these disease parameters, also in the group without peripheral involvement. Our study suggests that the BASDAI remains valid in assessing disease activity in AS patients with and without peripheral manifestations.

Entities:  

Mesh:

Year:  2011        PMID: 21989992     DOI: 10.1007/s10067-011-1872-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.

Authors:  J Braun; J Davis; M Dougados; J Sieper; S van der Linden; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

3.  The natural disease course of ankylosing spondylitis.

Authors:  S Carette; D Graham; H Little; J Rubenstein; P Rosen
Journal:  Arthritis Rheum       Date:  1983-02

4.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

5.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

Authors:  A Calin; J P Nakache; A Gueguen; H Zeidler; H Mielants; M Dougados
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

6.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

7.  Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis.

Authors:  H S Goie The; M M Steven; S M van der Linden; A Cats
Journal:  Br J Rheumatol       Date:  1985-08

Review 8.  Pathophysiology of ankylosing spondylitis: what's new?

Authors:  Thao Pham
Journal:  Joint Bone Spine       Date:  2008-11-25       Impact factor: 4.929

9.  Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

Authors:  J Brandt; A Khariouzov; J Listing; H Haibel; H Sörensen; L Grassnickel; M Rudwaleit; J Sieper; J Braun
Journal:  Arthritis Rheum       Date:  2003-06

10.  Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.

Authors:  I H Song; M Rudwaleit; J Listing; J Sieper
Journal:  Ann Rheum Dis       Date:  2008-11-24       Impact factor: 19.103

View more
  1 in total

Review 1.  Spondyloarthritis in North Africa: an update.

Authors:  Samy Slimani; Wafa Hamdi; Kawtar Nassar; Asgar Ali Kalla
Journal:  Clin Rheumatol       Date:  2021-02-09       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.